Literature DB >> 32096798

Ultrasound evaluation of complications after cardiovascular surgery in pediatric patients: A case series.

Takahiro Hosokawa1, Sio Suzuki2, Yutaka Tanami3, Yumiko Sato3, Yoshihiro Ko4, Koji Nomura4, Eiji Oguma5, Yoshitake Yamada6.   

Abstract

In contrast to computed tomography, ultrasound can be performed without radiation exposure, repeatedly performed by the patients' bedside. Hence, in this case series, we describe the evaluation of complications including hematoma, superficialsurgical site infection, mediastinitis, and pseudoaneurysm associated mediastinitis using ultrasound in pediatric patients after cardiovascular surgery. To our knowledge, no previous reports have evaluated such complications using ultrasound. Ultrasound may be useful for the early diagnosis of these complications, and in the selection of subsequent examinations such as computed tomography, resulting in the early initiation of intervention.

Entities:  

Mesh:

Year:  2020        PMID: 32096798     DOI: 10.11152/mu-1982

Source DB:  PubMed          Journal:  Med Ultrason        ISSN: 1844-4172            Impact factor:   1.611


  3 in total

Review 1.  Extracardiac Complications in Intensive Care Units after Surgical Repair for Congenital Heart Disease: Imaging Review with a Focus on Ultrasound and Radiography.

Authors:  Takahiro Hosokawa; Saki Shibuki; Yutaka Tanami; Yumiko Sato; Yoshihiro Ko; Koji Nomura; Eiji Oguma
Journal:  J Pediatr Intensive Care       Date:  2020-09-09

2.  Initial ultrasound evaluation of an anterior mediastinal mass ultimately diagnosed as T-cell acute lymphoblastic leukemia: a report of three cases in children.

Authors:  Takahiro Hosokawa; Mamoru Honda; Yuki Arakawa
Journal:  Radiol Case Rep       Date:  2022-07-30

Review 3.  Role of ultrasound in the treatment of pediatric infectious diseases: case series and narrative review.

Authors:  Takahiro Hosokawa; Yutaka Tanami; Yumiko Sato; Kuntaro Deguchi; Haruka Takei; Eiji Oguma
Journal:  World J Pediatr       Date:  2022-09-21       Impact factor: 9.186

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.